CSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact

Bulletin Express

08/05

CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.

Under the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.

The collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.

Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1173745599"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173745599\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173745599?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173745599","market":"hk","top_or_hot":-1,"title":"CSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.</p>\n<p>Under the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.</p>\n<p>The collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-08-05 18:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.</p>\n<p>Under the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.</p>\n<p>The collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石藥集團","start_time":0,"source_url":"","article_id":"1173745599","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173745599","pubTimestamp":1785924335,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团根据小分子研发协议从阿斯利康获得 1000 万美元里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.\nUnder the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.\nThe collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.\nShareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}